nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ALB—Furosemide—dilated cardiomyopathy	0.151	0.379	CbGbCtD
Tacrolimus—ABCB1—Lisinopril—dilated cardiomyopathy	0.131	0.33	CbGbCtD
Tacrolimus—ABCB1—Spironolactone—dilated cardiomyopathy	0.115	0.29	CbGbCtD
Tacrolimus—ABCA5—cardiac ventricle—dilated cardiomyopathy	0.0119	0.137	CbGeAlD
Tacrolimus—ABCA5—myocardium—dilated cardiomyopathy	0.0112	0.129	CbGeAlD
Tacrolimus—PPP3CA—cardiac ventricle—dilated cardiomyopathy	0.00802	0.0924	CbGeAlD
Tacrolimus—ABCA5—heart—dilated cardiomyopathy	0.00779	0.0898	CbGeAlD
Tacrolimus—PPP3CA—myocardium—dilated cardiomyopathy	0.00754	0.0869	CbGeAlD
Tacrolimus—ABCA5—cardiac atrium—dilated cardiomyopathy	0.00667	0.0768	CbGeAlD
Tacrolimus—FKBP1A—cardiac ventricle—dilated cardiomyopathy	0.00533	0.0614	CbGeAlD
Tacrolimus—PPP3CA—heart—dilated cardiomyopathy	0.00526	0.0607	CbGeAlD
Tacrolimus—FKBP1A—myocardium—dilated cardiomyopathy	0.00501	0.0578	CbGeAlD
Tacrolimus—PPP3CA—cardiac atrium—dilated cardiomyopathy	0.0045	0.0519	CbGeAlD
Tacrolimus—MTOR—heart—dilated cardiomyopathy	0.00389	0.0448	CbGeAlD
Tacrolimus—FKBP1A—heart—dilated cardiomyopathy	0.0035	0.0403	CbGeAlD
Tacrolimus—FKBP1A—cardiac atrium—dilated cardiomyopathy	0.00299	0.0345	CbGeAlD
Tacrolimus—ALB—heart—dilated cardiomyopathy	0.0024	0.0277	CbGeAlD
Tacrolimus—Alopecia—Spironolactone—dilated cardiomyopathy	0.00139	0.00396	CcSEcCtD
Tacrolimus—Oliguria—Lisinopril—dilated cardiomyopathy	0.00139	0.00395	CcSEcCtD
Tacrolimus—Deafness—Furosemide—dilated cardiomyopathy	0.00138	0.00394	CcSEcCtD
Tacrolimus—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00137	0.00391	CcSEcCtD
Tacrolimus—Gout—Lisinopril—dilated cardiomyopathy	0.00137	0.0039	CcSEcCtD
Tacrolimus—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00136	0.00388	CcSEcCtD
Tacrolimus—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00134	0.00383	CcSEcCtD
Tacrolimus—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00132	0.00375	CcSEcCtD
Tacrolimus—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00131	0.00374	CcSEcCtD
Tacrolimus—Thirst—Furosemide—dilated cardiomyopathy	0.0013	0.0037	CcSEcCtD
Tacrolimus—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00129	0.00369	CcSEcCtD
Tacrolimus—Neck pain—Lisinopril—dilated cardiomyopathy	0.00129	0.00369	CcSEcCtD
Tacrolimus—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00128	0.00364	CcSEcCtD
Tacrolimus—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00127	0.00362	CcSEcCtD
Tacrolimus—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00126	0.00358	CcSEcCtD
Tacrolimus—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00125	0.00356	CcSEcCtD
Tacrolimus—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00124	0.00354	CcSEcCtD
Tacrolimus—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00124	0.00354	CcSEcCtD
Tacrolimus—Malaise—Spironolactone—dilated cardiomyopathy	0.00123	0.00352	CcSEcCtD
Tacrolimus—Cystitis—Lisinopril—dilated cardiomyopathy	0.00123	0.00352	CcSEcCtD
Tacrolimus—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00123	0.00349	CcSEcCtD
Tacrolimus—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00121	0.00346	CcSEcCtD
Tacrolimus—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00121	0.00344	CcSEcCtD
Tacrolimus—Photophobia—Lisinopril—dilated cardiomyopathy	0.0012	0.00342	CcSEcCtD
Tacrolimus—Neuropathy—Lisinopril—dilated cardiomyopathy	0.0012	0.00342	CcSEcCtD
Tacrolimus—Urinary retention—Furosemide—dilated cardiomyopathy	0.00118	0.00335	CcSEcCtD
Tacrolimus—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00116	0.0033	CcSEcCtD
Tacrolimus—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00116	0.00329	CcSEcCtD
Tacrolimus—Discomfort—Spironolactone—dilated cardiomyopathy	0.00115	0.00328	CcSEcCtD
Tacrolimus—Dehydration—Furosemide—dilated cardiomyopathy	0.00115	0.00328	CcSEcCtD
Tacrolimus—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00114	0.00324	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00113	0.00322	CcSEcCtD
Tacrolimus—Confusional state—Spironolactone—dilated cardiomyopathy	0.00113	0.00321	CcSEcCtD
Tacrolimus—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00113	0.00321	CcSEcCtD
Tacrolimus—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00112	0.00319	CcSEcCtD
Tacrolimus—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00112	0.00319	CcSEcCtD
Tacrolimus—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00111	0.00317	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00111	0.00317	CcSEcCtD
Tacrolimus—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00109	0.00312	CcSEcCtD
Tacrolimus—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00109	0.00311	CcSEcCtD
Tacrolimus—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00108	0.00307	CcSEcCtD
Tacrolimus—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00107	0.00304	CcSEcCtD
Tacrolimus—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00106	0.00301	CcSEcCtD
Tacrolimus—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00105	0.00299	CcSEcCtD
Tacrolimus—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00105	0.00298	CcSEcCtD
Tacrolimus—Eczema—Lisinopril—dilated cardiomyopathy	0.00103	0.00294	CcSEcCtD
Tacrolimus—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00103	0.00294	CcSEcCtD
Tacrolimus—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00103	0.00293	CcSEcCtD
Tacrolimus—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00102	0.0029	CcSEcCtD
Tacrolimus—Injury—Lisinopril—dilated cardiomyopathy	0.00101	0.00288	CcSEcCtD
Tacrolimus—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00101	0.00287	CcSEcCtD
Tacrolimus—Somnolence—Spironolactone—dilated cardiomyopathy	0.000994	0.00283	CcSEcCtD
Tacrolimus—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000988	0.00282	CcSEcCtD
Tacrolimus—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000979	0.00279	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000976	0.00278	CcSEcCtD
Tacrolimus—Renal impairment—Lisinopril—dilated cardiomyopathy	0.000975	0.00278	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000965	0.00275	CcSEcCtD
Tacrolimus—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000964	0.00275	CcSEcCtD
Tacrolimus—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.000959	0.00273	CcSEcCtD
Tacrolimus—Arthritis—Lisinopril—dilated cardiomyopathy	0.000955	0.00272	CcSEcCtD
Tacrolimus—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000951	0.00271	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000945	0.00269	CcSEcCtD
Tacrolimus—Renal failure—Furosemide—dilated cardiomyopathy	0.000937	0.00267	CcSEcCtD
Tacrolimus—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000932	0.00266	CcSEcCtD
Tacrolimus—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.000928	0.00265	CcSEcCtD
Tacrolimus—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000928	0.00265	CcSEcCtD
Tacrolimus—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000921	0.00262	CcSEcCtD
Tacrolimus—Sweating—Furosemide—dilated cardiomyopathy	0.000914	0.0026	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000902	0.00257	CcSEcCtD
Tacrolimus—Face oedema—Lisinopril—dilated cardiomyopathy	0.000896	0.00255	CcSEcCtD
Tacrolimus—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00089	0.00254	CcSEcCtD
Tacrolimus—Urticaria—Spironolactone—dilated cardiomyopathy	0.000888	0.00253	CcSEcCtD
Tacrolimus—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000883	0.00252	CcSEcCtD
Tacrolimus—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000883	0.00252	CcSEcCtD
Tacrolimus—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00087	0.00248	CcSEcCtD
Tacrolimus—Dehydration—Lisinopril—dilated cardiomyopathy	0.000863	0.00246	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000848	0.00242	CcSEcCtD
Tacrolimus—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000845	0.00241	CcSEcCtD
Tacrolimus—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000839	0.00239	CcSEcCtD
Tacrolimus—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000839	0.00239	CcSEcCtD
Tacrolimus—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000836	0.00238	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000836	0.00238	CcSEcCtD
Tacrolimus—Visual impairment—Furosemide—dilated cardiomyopathy	0.000825	0.00235	CcSEcCtD
Tacrolimus—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000823	0.00235	CcSEcCtD
Tacrolimus—Gastritis—Lisinopril—dilated cardiomyopathy	0.000821	0.00234	CcSEcCtD
Tacrolimus—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000809	0.00231	CcSEcCtD
Tacrolimus—ABCB1—heart—dilated cardiomyopathy	0.000809	0.00933	CbGeAlD
Tacrolimus—Influenza—Lisinopril—dilated cardiomyopathy	0.000802	0.00229	CcSEcCtD
Tacrolimus—Asthma—Lisinopril—dilated cardiomyopathy	0.000802	0.00229	CcSEcCtD
Tacrolimus—Eye disorder—Furosemide—dilated cardiomyopathy	0.0008	0.00228	CcSEcCtD
Tacrolimus—Tinnitus—Furosemide—dilated cardiomyopathy	0.000798	0.00227	CcSEcCtD
Tacrolimus—Pruritus—Spironolactone—dilated cardiomyopathy	0.000791	0.00225	CcSEcCtD
Tacrolimus—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000787	0.00224	CcSEcCtD
Tacrolimus—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000781	0.00223	CcSEcCtD
Tacrolimus—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000781	0.00223	CcSEcCtD
Tacrolimus—Angiopathy—Furosemide—dilated cardiomyopathy	0.000776	0.00221	CcSEcCtD
Tacrolimus—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000773	0.0022	CcSEcCtD
Tacrolimus—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000772	0.0022	CcSEcCtD
Tacrolimus—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000765	0.00218	CcSEcCtD
Tacrolimus—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000765	0.00218	CcSEcCtD
Tacrolimus—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000762	0.00217	CcSEcCtD
Tacrolimus—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00075	0.00214	CcSEcCtD
Tacrolimus—Dysuria—Lisinopril—dilated cardiomyopathy	0.00075	0.00214	CcSEcCtD
Tacrolimus—Erythema—Furosemide—dilated cardiomyopathy	0.000745	0.00212	CcSEcCtD
Tacrolimus—Malnutrition—Furosemide—dilated cardiomyopathy	0.000745	0.00212	CcSEcCtD
Tacrolimus—Dizziness—Spironolactone—dilated cardiomyopathy	0.000739	0.00211	CcSEcCtD
Tacrolimus—Flatulence—Furosemide—dilated cardiomyopathy	0.000734	0.00209	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000732	0.00209	CcSEcCtD
Tacrolimus—Weight increased—Lisinopril—dilated cardiomyopathy	0.00073	0.00208	CcSEcCtD
Tacrolimus—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00073	0.00208	CcSEcCtD
Tacrolimus—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000726	0.00207	CcSEcCtD
Tacrolimus—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000724	0.00206	CcSEcCtD
Tacrolimus—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000719	0.00205	CcSEcCtD
Tacrolimus—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000716	0.00204	CcSEcCtD
Tacrolimus—Depression—Lisinopril—dilated cardiomyopathy	0.000713	0.00203	CcSEcCtD
Tacrolimus—Vomiting—Spironolactone—dilated cardiomyopathy	0.000711	0.00203	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000709	0.00202	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000705	0.00201	CcSEcCtD
Tacrolimus—Rash—Spironolactone—dilated cardiomyopathy	0.000705	0.00201	CcSEcCtD
Tacrolimus—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000704	0.00201	CcSEcCtD
Tacrolimus—Renal failure—Lisinopril—dilated cardiomyopathy	0.000703	0.002	CcSEcCtD
Tacrolimus—Vision blurred—Furosemide—dilated cardiomyopathy	0.000702	0.002	CcSEcCtD
Tacrolimus—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000701	0.002	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000701	0.002	CcSEcCtD
Tacrolimus—Headache—Spironolactone—dilated cardiomyopathy	0.0007	0.002	CcSEcCtD
Tacrolimus—Jaundice—Lisinopril—dilated cardiomyopathy	0.000697	0.00199	CcSEcCtD
Tacrolimus—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000695	0.00198	CcSEcCtD
Tacrolimus—Anaemia—Furosemide—dilated cardiomyopathy	0.000689	0.00196	CcSEcCtD
Tacrolimus—Sweating—Lisinopril—dilated cardiomyopathy	0.000686	0.00195	CcSEcCtD
Tacrolimus—Agitation—Furosemide—dilated cardiomyopathy	0.000685	0.00195	CcSEcCtD
Tacrolimus—Haematuria—Lisinopril—dilated cardiomyopathy	0.000682	0.00194	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000676	0.00193	CcSEcCtD
Tacrolimus—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000675	0.00192	CcSEcCtD
Tacrolimus—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000671	0.00191	CcSEcCtD
Tacrolimus—Vertigo—Furosemide—dilated cardiomyopathy	0.000669	0.00191	CcSEcCtD
Tacrolimus—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000668	0.0019	CcSEcCtD
Tacrolimus—Leukopenia—Furosemide—dilated cardiomyopathy	0.000667	0.0019	CcSEcCtD
Tacrolimus—Nausea—Spironolactone—dilated cardiomyopathy	0.000664	0.00189	CcSEcCtD
Tacrolimus—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000654	0.00186	CcSEcCtD
Tacrolimus—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000644	0.00183	CcSEcCtD
Tacrolimus—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000642	0.00183	CcSEcCtD
Tacrolimus—Hallucination—Lisinopril—dilated cardiomyopathy	0.000639	0.00182	CcSEcCtD
Tacrolimus—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000637	0.00182	CcSEcCtD
Tacrolimus—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000634	0.00181	CcSEcCtD
Tacrolimus—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000633	0.0018	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00063	0.0018	CcSEcCtD
Tacrolimus—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000629	0.00179	CcSEcCtD
Tacrolimus—Dry mouth—Furosemide—dilated cardiomyopathy	0.00062	0.00177	CcSEcCtD
Tacrolimus—Confusional state—Furosemide—dilated cardiomyopathy	0.000613	0.00175	CcSEcCtD
Tacrolimus—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000608	0.00173	CcSEcCtD
Tacrolimus—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000607	0.00173	CcSEcCtD
Tacrolimus—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000599	0.00171	CcSEcCtD
Tacrolimus—Shock—Furosemide—dilated cardiomyopathy	0.000598	0.0017	CcSEcCtD
Tacrolimus—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000596	0.0017	CcSEcCtD
Tacrolimus—Flushing—Lisinopril—dilated cardiomyopathy	0.000596	0.0017	CcSEcCtD
Tacrolimus—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000595	0.0017	CcSEcCtD
Tacrolimus—Skin disorder—Furosemide—dilated cardiomyopathy	0.000591	0.00168	CcSEcCtD
Tacrolimus—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000588	0.00168	CcSEcCtD
Tacrolimus—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000583	0.00166	CcSEcCtD
Tacrolimus—Anorexia—Furosemide—dilated cardiomyopathy	0.00058	0.00165	CcSEcCtD
Tacrolimus—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000579	0.00165	CcSEcCtD
Tacrolimus—Chills—Lisinopril—dilated cardiomyopathy	0.000576	0.00164	CcSEcCtD
Tacrolimus—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000574	0.00163	CcSEcCtD
Tacrolimus—Hypotension—Furosemide—dilated cardiomyopathy	0.000568	0.00162	CcSEcCtD
Tacrolimus—Alopecia—Lisinopril—dilated cardiomyopathy	0.000567	0.00162	CcSEcCtD
Tacrolimus—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000563	0.0016	CcSEcCtD
Tacrolimus—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000559	0.00159	CcSEcCtD
Tacrolimus—Erythema—Lisinopril—dilated cardiomyopathy	0.000559	0.00159	CcSEcCtD
Tacrolimus—Flatulence—Lisinopril—dilated cardiomyopathy	0.000551	0.00157	CcSEcCtD
Tacrolimus—Tension—Lisinopril—dilated cardiomyopathy	0.000549	0.00156	CcSEcCtD
Tacrolimus—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000547	0.00156	CcSEcCtD
Tacrolimus—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000546	0.00156	CcSEcCtD
Tacrolimus—Nervousness—Lisinopril—dilated cardiomyopathy	0.000543	0.00155	CcSEcCtD
Tacrolimus—Back pain—Lisinopril—dilated cardiomyopathy	0.000541	0.00154	CcSEcCtD
Tacrolimus—Somnolence—Furosemide—dilated cardiomyopathy	0.000541	0.00154	CcSEcCtD
Tacrolimus—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000537	0.00153	CcSEcCtD
Tacrolimus—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000529	0.00151	CcSEcCtD
Tacrolimus—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000527	0.0015	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000525	0.0015	CcSEcCtD
Tacrolimus—Fatigue—Furosemide—dilated cardiomyopathy	0.000524	0.00149	CcSEcCtD
Tacrolimus—Tremor—Lisinopril—dilated cardiomyopathy	0.000524	0.00149	CcSEcCtD
Tacrolimus—Constipation—Furosemide—dilated cardiomyopathy	0.00052	0.00148	CcSEcCtD
Tacrolimus—Pain—Furosemide—dilated cardiomyopathy	0.00052	0.00148	CcSEcCtD
Tacrolimus—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000519	0.00148	CcSEcCtD
Tacrolimus—Anaemia—Lisinopril—dilated cardiomyopathy	0.000517	0.00147	CcSEcCtD
Tacrolimus—Malaise—Lisinopril—dilated cardiomyopathy	0.000504	0.00144	CcSEcCtD
Tacrolimus—Vertigo—Lisinopril—dilated cardiomyopathy	0.000502	0.00143	CcSEcCtD
Tacrolimus—Syncope—Lisinopril—dilated cardiomyopathy	0.000501	0.00143	CcSEcCtD
Tacrolimus—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000501	0.00143	CcSEcCtD
Tacrolimus—Leukopenia—Lisinopril—dilated cardiomyopathy	0.0005	0.00143	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000497	0.00142	CcSEcCtD
Tacrolimus—Palpitations—Lisinopril—dilated cardiomyopathy	0.000494	0.00141	CcSEcCtD
Tacrolimus—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000491	0.0014	CcSEcCtD
Tacrolimus—Cough—Lisinopril—dilated cardiomyopathy	0.000488	0.00139	CcSEcCtD
Tacrolimus—Urticaria—Furosemide—dilated cardiomyopathy	0.000483	0.00138	CcSEcCtD
Tacrolimus—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000481	0.00137	CcSEcCtD
Tacrolimus—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000481	0.00137	CcSEcCtD
Tacrolimus—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000476	0.00136	CcSEcCtD
Tacrolimus—Myalgia—Lisinopril—dilated cardiomyopathy	0.000476	0.00136	CcSEcCtD
Tacrolimus—Chest pain—Lisinopril—dilated cardiomyopathy	0.000476	0.00136	CcSEcCtD
Tacrolimus—Anxiety—Lisinopril—dilated cardiomyopathy	0.000474	0.00135	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000473	0.00135	CcSEcCtD
Tacrolimus—Discomfort—Lisinopril—dilated cardiomyopathy	0.00047	0.00134	CcSEcCtD
Tacrolimus—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000465	0.00133	CcSEcCtD
Tacrolimus—Confusional state—Lisinopril—dilated cardiomyopathy	0.00046	0.00131	CcSEcCtD
Tacrolimus—Oedema—Lisinopril—dilated cardiomyopathy	0.000456	0.0013	CcSEcCtD
Tacrolimus—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000456	0.0013	CcSEcCtD
Tacrolimus—Infection—Lisinopril—dilated cardiomyopathy	0.000453	0.00129	CcSEcCtD
Tacrolimus—Shock—Lisinopril—dilated cardiomyopathy	0.000449	0.00128	CcSEcCtD
Tacrolimus—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000448	0.00128	CcSEcCtD
Tacrolimus—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000447	0.00127	CcSEcCtD
Tacrolimus—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000445	0.00127	CcSEcCtD
Tacrolimus—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000443	0.00126	CcSEcCtD
Tacrolimus—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000441	0.00126	CcSEcCtD
Tacrolimus—Asthenia—Furosemide—dilated cardiomyopathy	0.000436	0.00124	CcSEcCtD
Tacrolimus—Anorexia—Lisinopril—dilated cardiomyopathy	0.000435	0.00124	CcSEcCtD
Tacrolimus—Pruritus—Furosemide—dilated cardiomyopathy	0.00043	0.00123	CcSEcCtD
Tacrolimus—Hypotension—Lisinopril—dilated cardiomyopathy	0.000426	0.00121	CcSEcCtD
Tacrolimus—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000416	0.00119	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000416	0.00118	CcSEcCtD
Tacrolimus—Insomnia—Lisinopril—dilated cardiomyopathy	0.000413	0.00118	CcSEcCtD
Tacrolimus—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00041	0.00117	CcSEcCtD
Tacrolimus—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000407	0.00116	CcSEcCtD
Tacrolimus—Somnolence—Lisinopril—dilated cardiomyopathy	0.000406	0.00116	CcSEcCtD
Tacrolimus—Dizziness—Furosemide—dilated cardiomyopathy	0.000402	0.00115	CcSEcCtD
Tacrolimus—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000402	0.00114	CcSEcCtD
Tacrolimus—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000397	0.00113	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000394	0.00112	CcSEcCtD
Tacrolimus—Fatigue—Lisinopril—dilated cardiomyopathy	0.000393	0.00112	CcSEcCtD
Tacrolimus—Pain—Lisinopril—dilated cardiomyopathy	0.00039	0.00111	CcSEcCtD
Tacrolimus—Constipation—Lisinopril—dilated cardiomyopathy	0.00039	0.00111	CcSEcCtD
Tacrolimus—Vomiting—Furosemide—dilated cardiomyopathy	0.000387	0.0011	CcSEcCtD
Tacrolimus—Rash—Furosemide—dilated cardiomyopathy	0.000383	0.00109	CcSEcCtD
Tacrolimus—Dermatitis—Furosemide—dilated cardiomyopathy	0.000383	0.00109	CcSEcCtD
Tacrolimus—Headache—Furosemide—dilated cardiomyopathy	0.000381	0.00109	CcSEcCtD
Tacrolimus—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000376	0.00107	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000373	0.00106	CcSEcCtD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.000371	0.00224	CbGpPWpGaD
Tacrolimus—MTOR—CDC42 signaling events—RAF1—dilated cardiomyopathy	0.000366	0.00222	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.000364	0.0022	CbGpPWpGaD
Tacrolimus—Urticaria—Lisinopril—dilated cardiomyopathy	0.000362	0.00103	CcSEcCtD
Tacrolimus—PPP3CA—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.000361	0.00218	CbGpPWpGaD
Tacrolimus—Nausea—Furosemide—dilated cardiomyopathy	0.000361	0.00103	CcSEcCtD
Tacrolimus—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000361	0.00103	CcSEcCtD
Tacrolimus—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000361	0.00103	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.000356	0.00215	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000348	0.00211	CbGpPWpGaD
Tacrolimus—MTOR—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.000347	0.0021	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000343	0.00208	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000336	0.000958	CcSEcCtD
Tacrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAF1—dilated cardiomyopathy	0.000329	0.00199	CbGpPWpGaD
Tacrolimus—Asthenia—Lisinopril—dilated cardiomyopathy	0.000327	0.000933	CcSEcCtD
Tacrolimus—ALB—Folate Metabolism—SOD2—dilated cardiomyopathy	0.000325	0.00197	CbGpPWpGaD
Tacrolimus—Pruritus—Lisinopril—dilated cardiomyopathy	0.000323	0.00092	CcSEcCtD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.000317	0.00191	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.000316	0.00191	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.000316	0.00191	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.000315	0.00191	CbGpPWpGaD
Tacrolimus—MTOR—IRS-mediated signalling—RAF1—dilated cardiomyopathy	0.000314	0.0019	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.000313	0.00189	CbGpPWpGaD
Tacrolimus—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000312	0.00089	CcSEcCtD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000311	0.00188	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.00031	0.00188	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—GPX1—dilated cardiomyopathy	0.00031	0.00187	CbGpPWpGaD
Tacrolimus—MTOR—ErbB Signaling Pathway—EGFR—dilated cardiomyopathy	0.000309	0.00187	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events—RAF1—dilated cardiomyopathy	0.000305	0.00184	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—RAF1—dilated cardiomyopathy	0.000302	0.00183	CbGpPWpGaD
Tacrolimus—Dizziness—Lisinopril—dilated cardiomyopathy	0.000302	0.00086	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000299	0.00181	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—RAF1—dilated cardiomyopathy	0.000294	0.00178	CbGpPWpGaD
Tacrolimus—MTOR—Insulin receptor signalling cascade—RAF1—dilated cardiomyopathy	0.000294	0.00178	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.000294	0.00178	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000293	0.00177	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000292	0.00176	CbGpPWpGaD
Tacrolimus—MTOR—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.00029	0.00175	CbGpPWpGaD
Tacrolimus—Vomiting—Lisinopril—dilated cardiomyopathy	0.00029	0.000827	CcSEcCtD
Tacrolimus—Rash—Lisinopril—dilated cardiomyopathy	0.000288	0.00082	CcSEcCtD
Tacrolimus—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000287	0.000819	CcSEcCtD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	0.000286	0.00173	CbGpPWpGaD
Tacrolimus—Headache—Lisinopril—dilated cardiomyopathy	0.000286	0.000815	CcSEcCtD
Tacrolimus—MTOR—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000285	0.00172	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000282	0.00171	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.00028	0.00169	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—RAC1—dilated cardiomyopathy	0.00028	0.00169	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000274	0.00166	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	0.000272	0.00165	CbGpPWpGaD
Tacrolimus—Nausea—Lisinopril—dilated cardiomyopathy	0.000271	0.000772	CcSEcCtD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.000268	0.00162	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000265	0.0016	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.000265	0.0016	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000264	0.0016	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000264	0.0016	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000263	0.00159	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000263	0.00159	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.000261	0.00158	CbGpPWpGaD
Tacrolimus—ALB—Platelet degranulation—CD36—dilated cardiomyopathy	0.000259	0.00157	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NPPA—dilated cardiomyopathy	0.000259	0.00156	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000258	0.00156	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—EGFR—dilated cardiomyopathy	0.000257	0.00155	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PSEN2—dilated cardiomyopathy	0.000251	0.00152	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD36—dilated cardiomyopathy	0.000249	0.0015	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	0.000247	0.00149	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000246	0.00149	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000246	0.00149	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000246	0.00149	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000245	0.00148	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—RAF1—dilated cardiomyopathy	0.000245	0.00148	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00024	0.00145	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000238	0.00144	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—RAC1—dilated cardiomyopathy	0.000234	0.00142	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000228	0.00138	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000225	0.00136	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.00022	0.00133	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.000218	0.00132	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000213	0.00129	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000209	0.00127	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.000208	0.00126	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000207	0.00125	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000206	0.00124	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000203	0.00123	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NPPA—dilated cardiomyopathy	0.000201	0.00121	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.0002	0.00121	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.0002	0.00121	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000197	0.00119	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PSEN2—dilated cardiomyopathy	0.000194	0.00118	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000192	0.00116	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000192	0.00116	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000191	0.00115	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000189	0.00114	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000188	0.00114	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TTN—dilated cardiomyopathy	0.000187	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000187	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000187	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000187	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000186	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000186	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000185	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.000182	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000182	0.0011	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000179	0.00108	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000176	0.00106	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000174	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000174	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000174	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000173	0.00105	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000171	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000171	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000171	0.00103	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ITGB1—dilated cardiomyopathy	0.00017	0.00103	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ACTN2—dilated cardiomyopathy	0.000163	0.000983	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000162	0.000981	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	0.000161	0.000974	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000158	0.000955	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000158	0.000955	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000156	0.000942	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000156	0.000942	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—RAF1—dilated cardiomyopathy	0.000155	0.00094	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000154	0.000934	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	0.000151	0.000916	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000149	0.000903	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000147	0.000888	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	0.000146	0.000881	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000145	0.000876	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD36—dilated cardiomyopathy	0.000145	0.000876	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000143	0.000868	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000143	0.000863	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000142	0.00086	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.00014	0.000848	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000138	0.000836	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000138	0.000836	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VCL—dilated cardiomyopathy	0.000138	0.000836	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000137	0.00083	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—RAC1—dilated cardiomyopathy	0.000137	0.000825	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000136	0.000823	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000136	0.000821	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000135	0.000817	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000129	0.00078	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000129	0.000778	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000128	0.000776	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000128	0.000776	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000128	0.000773	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000127	0.000769	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—RAC1—dilated cardiomyopathy	0.000126	0.000762	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000125	0.000758	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	0.000124	0.000749	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	0.000123	0.000745	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000122	0.000738	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000121	0.000731	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000121	0.000731	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00012	0.000725	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.00012	0.000723	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.00012	0.000723	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—EGFR—dilated cardiomyopathy	0.00012	0.000723	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000119	0.000718	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000119	0.000717	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000117	0.00071	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000117	0.000707	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	0.000116	0.000704	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000115	0.000694	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000114	0.000687	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NPPA—dilated cardiomyopathy	0.000113	0.000682	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000113	0.000682	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000112	0.000679	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—EGFR—dilated cardiomyopathy	0.000111	0.000669	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PSEN2—dilated cardiomyopathy	0.000109	0.000661	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000109	0.000658	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000109	0.000657	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD36—dilated cardiomyopathy	0.000108	0.000656	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000108	0.000654	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	0.000107	0.000645	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—EGFR—dilated cardiomyopathy	0.000107	0.000644	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000107	0.000644	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000106	0.000641	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	0.000105	0.000637	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000104	0.00063	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—RAC1—dilated cardiomyopathy	0.000102	0.000618	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TAZ—dilated cardiomyopathy	0.0001	0.000607	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.91e-05	0.000599	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—RAC1—dilated cardiomyopathy	9.81e-05	0.000593	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	9.79e-05	0.000592	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—RAC1—dilated cardiomyopathy	9.77e-05	0.000591	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.77e-05	0.000591	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	9.35e-05	0.000565	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	9.35e-05	0.000565	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.29e-05	0.000562	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SDHA—dilated cardiomyopathy	9.07e-05	0.000549	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—RAF1—dilated cardiomyopathy	9.05e-05	0.000547	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RAC1—dilated cardiomyopathy	8.83e-05	0.000534	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.81e-05	0.000533	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	8.79e-05	0.000531	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AGT—dilated cardiomyopathy	8.43e-05	0.00051	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—RAF1—dilated cardiomyopathy	8.36e-05	0.000505	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—EGFR—dilated cardiomyopathy	8.15e-05	0.000493	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	7.95e-05	0.000481	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.65e-05	0.000463	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.57e-05	0.000458	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ITGB1—dilated cardiomyopathy	7.41e-05	0.000448	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	7.18e-05	0.000434	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	7.07e-05	0.000427	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	6.94e-05	0.00042	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RAC1—dilated cardiomyopathy	6.84e-05	0.000414	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.8e-05	0.000411	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.8e-05	0.000411	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.79e-05	0.000411	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—RAF1—dilated cardiomyopathy	6.78e-05	0.00041	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AGT—dilated cardiomyopathy	6.54e-05	0.000395	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—RAF1—dilated cardiomyopathy	6.51e-05	0.000394	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—RAF1—dilated cardiomyopathy	6.48e-05	0.000392	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.32e-05	0.000382	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD36—dilated cardiomyopathy	6.32e-05	0.000382	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—dilated cardiomyopathy	6.21e-05	0.000375	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.12e-05	0.00037	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RAC1—dilated cardiomyopathy	5.95e-05	0.00036	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—CD36—dilated cardiomyopathy	5.92e-05	0.000358	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RAF1—dilated cardiomyopathy	5.85e-05	0.000354	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	5.76e-05	0.000348	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—dilated cardiomyopathy	5.73e-05	0.000347	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—RAC1—dilated cardiomyopathy	5.58e-05	0.000337	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.53e-05	0.000335	CbGpPWpGaD
Tacrolimus—MTOR—Disease—RAC1—dilated cardiomyopathy	5.5e-05	0.000332	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	5.41e-05	0.000327	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.39e-05	0.000326	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.23e-05	0.000316	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.96e-05	0.0003	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	4.9e-05	0.000296	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.85e-05	0.000293	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.85e-05	0.000293	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—dilated cardiomyopathy	4.65e-05	0.000281	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.61e-05	0.000279	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RAF1—dilated cardiomyopathy	4.54e-05	0.000274	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.46e-05	0.00027	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—dilated cardiomyopathy	4.44e-05	0.000269	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.26e-05	0.000258	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—dilated cardiomyopathy	4.01e-05	0.000243	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	3.96e-05	0.000239	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RAF1—dilated cardiomyopathy	3.95e-05	0.000239	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	3.86e-05	0.000233	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RAC1—dilated cardiomyopathy	3.85e-05	0.000233	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—RAF1—dilated cardiomyopathy	3.7e-05	0.000224	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AGT—dilated cardiomyopathy	3.68e-05	0.000222	CbGpPWpGaD
Tacrolimus—MTOR—Disease—RAF1—dilated cardiomyopathy	3.64e-05	0.00022	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	3.47e-05	0.00021	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.2e-05	0.000194	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.11e-05	0.000188	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	2.86e-05	0.000173	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.81e-05	0.00017	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	2.79e-05	0.000169	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—dilated cardiomyopathy	2.71e-05	0.000164	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RAF1—dilated cardiomyopathy	2.55e-05	0.000154	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	2.51e-05	0.000152	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—dilated cardiomyopathy	2.5e-05	0.000151	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GPX1—dilated cardiomyopathy	2.46e-05	0.000149	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CD36—dilated cardiomyopathy	2.4e-05	0.000145	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AGT—dilated cardiomyopathy	2.16e-05	0.000131	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.16e-05	0.000131	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.1e-05	0.000127	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.89e-05	0.000114	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—dilated cardiomyopathy	1.75e-05	0.000106	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.33e-05	8.04e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.3e-05	7.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.17e-05	7.05e-05	CbGpPWpGaD
